{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:44:27Z","timestamp":1790502267427,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700482"],"award-info":[{"award-number":["81700482"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970483"],"award-info":[{"award-number":["81970483"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030310211"],"award-info":[{"award-number":["2017A030310211"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["A2017292"],"award-info":[{"award-number":["A2017292"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background and Aims:<\/jats:bold> Angiotensin-converting enzyme II (ACE2) is the key molecule for understanding the pathophysiology of COVID-19. The risk of COVID-19 and impact of immunosuppressive treatment on disease course in patients with inflammatory bowel disease (IBD) remain controversial. We aimed to determine the change of intestinal ACE2 expression before and after biologics treatment including anti-tumor necrosis factor \u03b1 (anti-TNF\u03b1), anti-integrin, and anti-interleukin (IL)12\/23 in IBD patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We analyzed the ACE2 expression through the public database of paired intestinal biopsies from IBD patients before and after biologic therapy. Change of ACE2 RNA and protein expression were validated in two independent cohorts (Birmingham cohort and Guangzhou cohort). The correlation between ACE2 expression and disease activity was also analyzed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Mining information from the GEO database showed that compared with healthy control, intestinal ACE2 expression was downregulated in ileum of CD patients, while upregulated in colon of both CD and UC patients. Colonic ACE2 RNA expression was decreased significantly in patients responding to anti-TNF\u03b1 but not anti-integrin and anti-IL12\/23, which was validated in the Birmingham cohort. Using the Guangzhou cohort including 53 patients matched by pre- and post-anti-TNF\u03b1 therapy, colonic ACE2 protein expression was significantly downregulated after anti-TNF\u03b1 treatment in responders (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) rather than non-responders. Colonic ACE2 expression was significantly higher in patients with severe histologically active disease compared with those with moderate (<jats:italic>P<\/jats:italic> &amp;lt; 0.0001) and mild (<jats:italic>P<\/jats:italic> = 0.0002) histologically active disease.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Intestinal inflammation influences the expression of intestinal ACE2 in IBD patients, with different alterations in the ileum and colon. Colonic ACE2 expression was downregulated after anti-TNF\u03b1 therapy in IBD patients responding to treatment. This might provide new clues regarding the risk of SARS-CoV-2 infection and the potential benefit of sustaining anti-TNF\u03b1 treatment in patients with IBD.<\/jats:p>","DOI":"10.3389\/fmed.2020.613475","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T04:19:45Z","timestamp":1610511585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19"],"prefix":"10.3389","volume":"7","author":[{"given":"Xiao-Zhi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Shen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Nan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Iacucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2951-z","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1053\/j.gastro.2020.03.045","article-title":"Multiomics evaluation of gastrointestinal and other clinical characteristics of COVID-19","volume":"158","author":"Du","year":"2020","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1136\/gutjnl-2020-320953","article-title":"Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process","volume":"69","author":"Zhang","year":"2020","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1053\/j.gastro.2020.02.055","article-title":"Evidence for gastrointestinal infection of SARS-CoV-2","volume":"158","author":"Xiao","year":"2020","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1136\/gutjnl-2020-320832","article-title":"Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus","volume":"69","author":"Liang","year":"2020","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s41591-020-0912-6","article-title":"Infection of bat and human intestinal organoids by SARS-CoV-2","volume":"26","author":"Zhou","year":"2020","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1126\/science.abc1669","article-title":"SARS-CoV-2 productively infects human gut enterocytes","volume":"369","author":"Lamers","year":"2020","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2468-1253(20)30121-7","article-title":"Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China","volume":"5","author":"An","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/apt.15804","article-title":"2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases","volume":"52","author":"Taxonera","year":"2020","journal-title":"Aliment Pharm Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.cgh.2020.04.071","article-title":"Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts","volume":"18","author":"Allocca","year":"2020","journal-title":"Clin Gastroenterol H"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1136\/gutjnl-2020-321411","article-title":"Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study","volume":"69","author":"Bezzio","year":"2020","journal-title":"Gut"},{"key":"B12","unstructured":"BrennerEJ\n            UngaroRC\n            ColombelJF\n            KappelmanMD\n          SECURE-IBD Database Public Data Update"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa185","article-title":"Intestinal receptor of SARS-CoV-2 in inflamed IBD tissue seems downregulated by HNF4A in ileum and upregulated by interferon regulating factors in colon","author":"Verstockt","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.21.109124","article-title":"Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease","author":"Su\u00e1rez-Fari\u00f1as","year":"2020","journal-title":"Gastroenterology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ibd\/izaa085","article-title":"Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD","volume":"26","author":"Burgue\u00f1o","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1261\/rna.053959.115","article-title":"How many biological replicates are needed in an RNA-seq experiment and which differential expression tool should you use?","volume":"22","author":"Schurch","year":"2016","journal-title":"RNA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/gutjnl-2019-318512","article-title":"Imbalance of the renin\u2013angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?","volume":"69","author":"Garg","year":"2020","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","article-title":"Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active crohn's disease","volume":"157","author":"Danese","year":"2019","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.gastro.2008.10.051","article-title":"Infliximab prevents crohn's disease recurrence after ileal resection","volume":"136","author":"Regueiro","year":"2009","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e7984","DOI":"10.1371\/journal.pone.0007984","article-title":"Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment","volume":"4","author":"Arijs","year":"2009","journal-title":"PLoS ONE"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/ajg.2011.83","article-title":"Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis","volume":"106","author":"Toedter","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","article-title":"Effect of vedolizumab (anti-\u03b14\u03b27-integrin) therapy on histological healing and mucosal gene expression in patients with UC","volume":"67","author":"Arijs","year":"2017","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.gastro.2018.05.028","article-title":"Abnormal small intestinal epithelial microvilli in patients with crohn's disease","volume":"155","author":"VanDussen","year":"2018","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"a26","DOI":"10.1093\/crocol\/otaa026","article-title":"The risk of SARS-CoV-2 in immunosuppressed IBD patients","volume":"2","author":"Higgins","year":"2020","journal-title":"Crohns Colitis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/gutjnl-2020-321269","article-title":"COVID-19 and immunomodulation in IBD","volume":"69","author":"Neurath","year":"2020","journal-title":"Gut"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/ecco-jcc\/jjaa061","article-title":"Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","volume":"14","author":"Monteleone","year":"2020","journal-title":"J Crohns Colitis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/jmv.26139","article-title":"Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection","volume":"92","author":"Zhuang","year":"2020","journal-title":"J Med Virol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.087","article-title":"The course of Covid 19 in inflammatory bowel disease: protective role of TNF antagonists response to: corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry","author":"Cappello","year":"2020","journal-title":"Gastroenterology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"2","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","article-title":"Molecular mechanism of action of anti-tumor necrosis factor antibodies ininflammatory bowel diseases","volume":"22","author":"Billmeier","year":"2016","journal-title":"World J Gastroentero"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"The Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/jcp.24794","article-title":"MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS","volume":"230","author":"He","year":"2015","journal-title":"J Cell Physiol"},{"key":"B37","first-page":"75","article-title":"The renin-angiotensin system and its vasoactive metabolite angiotensin-(1-7) in the mechanism of the healing of preexisting gastric ulcers. The involvement of Mas receptors, nitric oxide, prostaglandins and proinflammatory cytokines","volume":"67","author":"Pawlik","year":"2016","journal-title":"J Physiol Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.bbrc.2020.10.002","article-title":"ACE2 contributes to the maintenance of mouse epithelial barrier function","volume":"533","author":"Yu","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature11228","article-title":"ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation","volume":"487","author":"Hashimoto","year":"2012","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00011-009-0053-3","article-title":"Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice","volume":"58","author":"Byrnes","year":"2009","journal-title":"Inflamm Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn's disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","author":"Ungaro","year":"2020","journal-title":"Gut"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide crohn's disease into ileum-dominant and isolated colonic diseases?","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol H"},{"key":"B44","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312673","article-title":"Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?","volume":"66","author":"Subramanian","year":"2017","journal-title":"Gut"},{"key":"B45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00428-017-2156-5","article-title":"Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?","volume":"472","author":"Pai","year":"2018","journal-title":"Virchows Arch"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.613475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T13:35:33Z","timestamp":1610544933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.613475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":45,"alternative-id":["10.3389\/fmed.2020.613475"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.613475","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"article-number":"613475"}}